Lupin Limited
All news and filings related to Lupin Limited.
View all news & filings- Low impact
Lupin Limited Closes Trading Window from Oct 1 for Q2 FY27 Results
Lupin Limited's trading window will be closed from October 1, 2026. The closure is in anticipation of the unaudited financial results for the quarter and half-year ending September 30, 2026. The trading window will reopen 48 hours after the results declaration.
Read the summary - Medium impact
Lupin Receives Tentative U.S. FDA Approval for Apixaban Oral Suspension
Lupin Limited received tentative U.S. FDA approval for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway. This oral liquid formulation offers an alternative for patients needing anticoagulation therapy. Manufacturing will occur at Lupin's New Jersey facility upon final approval.
Read the summary - Low impact
Lupin to Participate in Kotak & J.P. Morgan Healthcare Conferences
Lupin Limited will participate in the Kotak Healthcare Conference on September 17, 2026, and the J.P. Morgan India Conference on September 21, 2026. Both events are in-person group meetings.
Read the summary - Medium impact
Lupin receives U.S. FDA approval for Modafinil Tablets, USP
Lupin Limited received U.S. FDA approval for Modafinil Tablets USP, 100 mg and 200 mg. The drug is indicated to improve wakefulness in adult patients with narcolepsy, OSA, or SWD. The RLD, Provigil®, had estimated annual U.S. sales of USD 70.7 million (approx. ₹590 crore).
Read the summary - Low impact
Lupin Limited receives 'Strong' ESG rating from CRISIL for FY26
Lupin Limited has received an ESG rating of 'CRISIL ESG 69' and a Core ESG rating of 'CRISIL Core ESG 65' for FY26 from CRISIL ESG Ratings & Analytics Ltd. The company has been placed in the 'Strong' category based on this independent assessment.
Read the summary - Low impact
Lupin Limited Receives 'Adequate' ESG Rating from ESG Risk Assessments & Insights
Lupin Limited has received an ESG Rating of '60', categorizing it as 'Adequate'. The assessment was independently conducted by ESG Risk Assessments & Insights Limited using publicly available data.
Read the summary - Medium impact
Lupin inks exclusive pact with Visus Therapeutics for YUVEZZI™ in Europe
Lupin's subsidiary VISUfarma B.V. secured exclusive rights to commercialize YUVEZZI™ in Europe from Visus Therapeutics. The deal involves a €20 million investment and up to €55 million in milestone payments, plus royalties. This partnership aims to boost Lupin's ophthalmology portfolio and specialty business in European markets.
Read the summary - Low impact
Lupin Limited Announces Demise of Senior Management Personnel, Dr. Sofia Mumtaz
Lupin Limited announced the sad demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business. Dr. Mumtaz passed away on August 17, 2026. This information is disclosed as per SEBI Listing Regulations.
Read the summary - Medium impact
Lupin Receives U.S. FDA Approval for Pitolisant Tablets
Lupin Limited announced it received final U.S. FDA approval for its Pitolisant Tablets (4.45 mg and 17.8 mg). The drug is bioequivalent to Wakix® for approved indications. This marks a significant product approval for the global pharmaceutical company.
Read the summary - High impact
Lupin Reports Record Q1 FY27 with ₹8,277 Cr Revenue, EBITDA ₹2,464 Cr
Lupin reported record Q1 FY27 results with revenue at ₹8,277 Cr and EBITDA at ₹2,464 Cr, a 32% and 50% YoY increase respectively. U.S. sales reached USD 366 million. India business grew 13.9% YoY. The company reaffirmed full-year guidance of high single-digit revenue growth and 25% EBITDA margins.
Read the summary - Medium impact
Lupin Receives US FDA Approval for Sodium Zirconium Cyclosilicate Oral Suspension
Lupin Limited announced US FDA approval for its Sodium Zirconium Cyclosilicate for Oral Suspension. The drug is bioequivalent to Lokelma® and treats hyperkalemia in adults. The U.S. market for the RLD had estimated annual sales of USD 568 million.
Read the summary - Low impact
Lupin Limited to Participate in Multiple Investor Meets and Conferences in August-September 2026
Lupin Limited will participate in multiple investor events from August 13 to September 1, 2026. These include conferences organized by Equirus, Emkay, Motilal Oswal, Antique Healthcare, and Ashwamedh Elara. All meetings are in-person group interactions.
Read the summary - Medium impact
Lupin Limited Publishes Newspaper Advertisement for Q1 FY27 Unaudited Financial Results
Lupin Limited published its unaudited financial results for Q1 FY27, ending June 30, 2026. Total income from operations was ₹26,023.5 crore. Profit After Tax (PAT) stood at ₹21,546.2 crore. Earnings Per Share (EPS) was ₹30.95.
Read the summary - Low impact
Lupin Limited: Audio Recording of Q1 FY27 Earnings Call Available
Lupin Limited has released the audio recording of its Q1 FY27 earnings call. The call, which discussed the company's unaudited financial results for the quarter ended June 30, 2026, took place on August 7, 2026.
Read the summary - High impact
Lupin Q1 FY27 Results: Sales Surge 33% YoY to ₹82,172 Mn, EBITDA Grows 50% YoY
Lupin Limited reported Q1 FY27 results with sales at ₹82,172 million, up 33% YoY. EBITDA increased 50% YoY to ₹24,635 million, with margins at 30.0%. Net income grew 16% YoY to ₹14,150 million. Key markets India and North America showed strong performance.
Read the summary - High impact
Lupin Q1 FY27 Results: Sales Surge 33% YoY to ₹82,172 Crore, EBITDA Up 50%
Lupin Limited reported Q1 FY27 results with net sales surging 33.3% YoY to ₹82,172 crore. EBITDA grew 50.1% to ₹2,463.5 crore, with margins at 30.0%. Net income rose 16.1% to ₹1,415 crore. Key drivers included strong growth in North America and India, along with new product launches and regulatory approvals.
Read the summary - High impact
Lupin Q1 FY27: Sales Surge 33.3% to ₹82,172 Crore, PAT Rises 16% to ₹14,170 Crore
Lupin Limited reported Q1 FY27 results with sales up 33.3% YoY to ₹82,172 crore. PAT increased 16.0% to ₹14,170 crore. EBITDA grew 42.8% to ₹25,799 crore. U.S. sales surged 42.9% to ₹34,348 crore. India sales rose 13.9% to ₹23,796 crore.
Read the summary - Medium impact
Lupin Limited's 44th AGM: All resolutions passed, ₹18 dividend declared
Lupin Limited's 44th AGM on August 4, 2026, saw all five resolutions passed. Key approvals included the FY26 financial statements and a final dividend of ₹18 per share. Mr. Nilesh D. Gupta was re-appointed as Director, and Deloitte Haskins & Sells Chartered Accountants LLP appointed as Statutory Auditors. Cost auditor remuneration was also ratified.
Read the summary - Medium impact
Lupin Receives US FDA Approval for Diazepam Injection USP Prefilled Syringes
Lupin Limited received U.S. FDA approval for its Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), Single-Dose Prefilled Syringes. The product is bioequivalent to Valium® Injection and is indicated for anxiety disorders. The U.S. market for this drug had estimated annual sales of USD 77.9 million (₹647.9 crore) as of May 2026.
Read the summary - Medium impact
Lupin Launches Sugammadex Injection in US After FDA Approval
Lupin Limited announced the U.S. FDA approval and subsequent launch of its Sugammadex Injection in the United States. The injection is a bioequivalent to Merck's Bridion® Injection and is used for reversing neuromuscular blockade in surgical patients.
Read the summary - Low impact
Lupin Limited Schedules Q1 FY27 Earnings Call for August 7, 2026
Lupin Limited will host its Q1 FY27 earnings call on August 7, 2026, at 16:30 IST. Registration for the Zoom call is available.
Read the summary - Medium impact
Lupin grants exclusive license for two oncology programs to Kaveri Therapeutics for 82.2% equity stake
Lupin Limited's subsidiary granted exclusive perpetual license for two oncology programs (LNP7547 & LNP8701) to Kaveri Therapeutics. Lupin received an 82.2% equity stake in Kaveri, valued at USD 1.6 million. Kaveri will advance these programs through clinical trials and raise additional capital. Transaction completed on July 20, 2026.
Read the summary - Low impact
Lupin Limited Announces 44th Annual General Meeting on August 4, 2026
Lupin Limited will hold its 44th Annual General Meeting on August 4, 2026, at 4:00 PM IST. The meeting will be conducted via Video Conferencing and Other Audio Visual Means. Details about e-voting are also provided.
Read the summary - Medium impact
Lupin Limited recognized as a Top Employer in India by Great Place To Work® India 2026
Lupin Limited has been named among India's Best Employers in the Nation Builders Category 2026 by Great Place To Work® India. It ranked among the Top 14 organizations nationally, reflecting its commitment to fostering a culture of purpose, trust, and inclusion, and its contributions to nation-building.
Read the summary - Low impact
Lupin Limited Releases Business Responsibility and Sustainability Report for FY 2025-26
Lupin Limited released its Business Responsibility and Sustainability Report for FY 2025-26. The report details ESG performance, including a 41% reduction in Scope-1 and Scope-2 emissions and 33% renewable electricity usage in India. Key targets include 15% women employees by 2030 and new product launches by 2028.
Read the summary - Low impact
Lupin Limited Files SEBI Regulation 74(5) Certificate for Q1 FY27
Lupin Limited filed its quarterly certificate under SEBI Regulation 74(5) for the period ending June 30, 2026. The company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed the processing of dematerialised securities.
Read the summary - Low impact
Lupin Debuts on TIME & Statista World's Most Sustainable Companies 2026 List
Lupin Limited debuted on TIME and Statista’s World’s Most Sustainable Companies 2026 list, ranking 318th. The recognition highlights the company's ESG progress, including CDP ‘A’ ratings and an S&P Global CSA score of 91.
Read the summary - Medium impact
Lupin's Somerset Facility Receives U.S. FDA EIR with VAI Classification
Lupin Limited received a satisfactory Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification from the U.S. FDA for its Somerset, New Jersey facility. The inspection concluded on April 17, 2026. This outcome underscores Lupin's commitment to quality and compliance.
Read the summary - Low impact
Lupin Limited: Trading Window Closed July 1, 2026 for Q1 FY27 Results
Lupin Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. The date for the board meeting to approve these results will be announced later.
Read the summary - Medium impact
Lupin Receives Tentative FDA Approval for Enzalutamide Tablets
Lupin Limited received tentative U.S. FDA approval for its Enzalutamide Tablets (40 mg, 80 mg, 120 mg, 160 mg). The 40 mg and 80 mg strengths are bioequivalent to Xtandi® Tablets. The higher strengths offer additional dosing options.
Read the summary - Medium impact
Lupin Launches Azilsartan Medoxomil Tablets in US; First-to-File
Lupin has launched Azilsartan Medoxomil Tablets in the US after FDA approval. The product is bioequivalent to Edarbi® and is indicated for hypertension treatment. Lupin is the exclusive first-to-file and eligible for 180-day exclusivity. The estimated annual sales of the RLD were USD 53.5 million (₹446.9 crore).
Read the summary - High impact
Lupin's RanluspecTM Receives U.S. FDA Approval as Interchangeable Biosimilar
Lupin Limited announced U.S. FDA approval for RanluspecTM (ranibizumab-hkdz), an interchangeable biosimilar to Lucentis®. It's the only interchangeable biosimilar ranibizumab approved in the U.S., available in vials and pre-filled syringes. This approval aims to increase patient access to advanced vision therapies.
Read the summary - Medium impact
Lupin and Natco Receive U.S. FDA Approval for Eribulin Mesylate Injection
Lupin and Natco received U.S. FDA approval for Eribulin Mesylate Injection. The drug is bioequivalent to Halaven® Injection and is used for metastatic breast cancer and liposarcoma. The RLD had estimated annual sales of USD 43.7 million in the U.S.
Read the summary - Medium impact
Lupin gets US FDA nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets
Lupin Limited received U.S. FDA approval for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride Tablets. The product is bioequivalent to Sutab® Tablets and Lupin is eligible for 180-day generic exclusivity. The reference drug had estimated U.S. sales of USD 132.8 million.
Read the summary - Low impact
Lupin subsidiary's minority shareholding acquisition in Multicare Pharma delayed to July 2026
Lupin Limited's subsidiary, Nanomi B.V., has delayed its acquisition of minority shareholding in Multicare Pharmaceuticals Philippines, Inc. The transaction, initially expected by end-May 2026, is now projected to close in July 2026, pending closing conditions.
Read the summary - Medium impact
Lupin's LNP8701 Phase 1 Data Accepted for ASCO 2026 Meeting
Lupin's Phase 1a trial data for LNP8701, a novel SOS1 inhibitor, accepted for ASCO 2026 Annual Meeting (May 29-June 2). LNP8701 showed favorable safety, tolerability, and anti-tumor activity. Two patients completed 12 cycles, one completed 14 cycles with stable disease. Phase 1b trial ongoing.
Read the summary - Medium impact
Lupin's Ankleshwar Facility Receives Establishment Inspection Report (EIR) from U.S. FDA
Lupin Limited announced its Ankleshwar facility received the Establishment Inspection Report (EIR) from the U.S. FDA. The EIR follows a product-specific Pre-Approval Inspection conducted from March 2 to March 7, 2026. This outcome highlights Lupin's commitment to quality and regulatory compliance.
Read the summary - Low impact
Lupin Limited to Participate in Multiple Institutional Investor Events in Early June
Lupin Limited will participate in three investor events in early June 2026: BofA Securities India Conference (June 2), Morgan Stanley India Investment Forum (June 3), and Citi India Conference (June 4). These are in-person group meetings.
Read the summary - Medium impact
Lupin Gets China Approval for Oseltamivir Phosphate Oral Suspension
Lupin Limited has received China's NMPA approval for its Oseltamivir Phosphate oral suspension in partnership with Yabao Pharmaceuticals. This marks Lupin's debut in the Chinese market. The medication is indicated for influenza treatment and prevention in pediatric and older age groups.
Read the summary - Medium impact
Lupin debuts in Dow Jones Best-in-Class Indices 2026 for ESG excellence
Lupin Limited has been included in the Dow Jones Best-in-Class (DJBIC) Indices 2026, featuring in both the DJBIC World Index and DJBIC Emerging Markets Index. This recognition highlights the company's strong ESG performance, following its top 1% ranking in the S&P Global CSA 2025. The inclusion reinforces Lupin's commitment to sustainable growth and responsible business practices.
Read the summary - Medium impact
Lupin Gets US FDA Tentative Approval for COPD Drug Revefenacin
Lupin Limited announced tentative U.S. FDA approval for its Revefenacin Inhalation Solution for COPD maintenance treatment. The drug is bioequivalent to Mylan's Yupelri®. The reference drug had estimated U.S. sales of USD 260.7 million in March 2026.
Read the summary - Medium impact
Lupin Launches Advanced Neuro-Rehabilitation Center 'Atharv Ability' in Delhi
Lupin Limited has launched 'Atharv Ability,' an advanced neuro-rehabilitation center in Delhi. This facility offers specialized care for neurological disorders, expanding access to technology-enabled treatments in North India. This marks the third such center by Lupin, following launches in Mumbai and Hyderabad.
Read the summary - High impact
Lupin Limited Q4 FY26 Earnings Call Transcript Released
Lupin Limited released its Q4 FY26 earnings call transcript on May 8, 2026. The company reported record revenues and profitability for FY26. Q4 FY26 revenue grew 32% YoY to ₹7,475 crore, with EBITDA up 68% YoY to ₹2,171 crore. Full-year revenue was ₹27,958 crore (up 23% YoY). The US business grew 40% YoY to USD 1.3 billion. The company expects high single-digit revenue growth and ~25% EBITDA margins for FY27.
Read the summary - Medium impact
Lupin Receives U.S. FDA Approval for Famotidine Injection USP
Lupin Limited received U.S. FDA approval for Famotidine Injection USP. The drug is bioequivalent to Pepcid® Injection and will be manufactured in India. Famotidine Injection had estimated U.S. sales of USD 8.7 million in March 2026.
Read the summary - Low impact
Lupin Limited Publishes Audited Financial Results for Q4 FY26
Lupin Limited published audited financial results for the quarter and year ended March 31, 2026. The disclosure was made as per SEBI LODR Regulations. The company is headquartered in Mumbai.
Read the summary - Low impact
Lupin Limited: Audio Recording of Q4 FY26 Earnings Call Available
Lupin Limited has released the audio recording of its Q4 FY26 Earnings Call, which took place on May 8, 2026. The recording is accessible on the company's website.
Read the summary - High impact
Lupin Q4 FY26 Results: Sales ₹73,919 Crore, PAT ₹14,604 Crore, Up 33% & 89% YoY
Lupin reported Q4 FY26 results with Net Sales at ₹73,919 crore (up 33% YoY) and Net Income at ₹14,604 crore (up 89% YoY). EBITDA grew 68% to ₹21,711 crore, with margins at 29.4%. North America sales surged 55%, while India grew 12%. The company completed the VISUfarma acquisition and received European Commission approval for biosimilar Ranibizumab.
Read the summary - High impact
Lupin FY26 Revenue Surges 23.9% to ₹2,74,875 Crore, Q4 Profit Jumps 87.7%
Lupin Limited reported FY2026 results with sales of ₹2,74,875 crore, up 23.9%. Q4 FY2026 PAT grew 87.7% to ₹14,687 crore. U.S. sales surged 46.0% to ₹1,16,783 crore. The company recommended a 900% dividend.
Read the summary - Medium impact
Lupin Limited Recommends Deloitte Haskins & Sells as New Statutory Auditors
Lupin Limited's Board of Directors has recommended Deloitte Haskins & Sells LLP as the new Statutory Auditors for a five-year term. This follows the completion of the current auditors' second term at the 44th AGM. Shareholder approval is pending at the upcoming AGM.
Read the summary - Medium impact
Lupin Recommends Dividend of ₹18/Share; FY26 Financial Results Announced
Lupin Limited recommended a dividend of ₹18 per share for FY26. The company announced audited standalone and consolidated financial results for the year ended March 31, 2026. Standalone net profit was ₹63,665.6 million on revenue of ₹195,126.6 million. Consolidated net profit was ₹53,554.7 million on revenue of ₹279,580.3 million.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio